FIELD: biotechnology.
SUBSTANCE: what is presented is using a composition containing an anti-AGE antibody for treating metastatic cancer and/or preventing cancer metastases in an individual. Anti-AGE antibody binds with carboxymethyllysine modified protein.
EFFECT: invention provides effective destruction of metastatic cancer cells or potentially malignant neoplastic cells.
17 cl, 4 dwg, 11 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AGE ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2766209C2 |
| MONOSPECIFIC AND BISPECIFIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION FOR CANCER TREATMENT | 2018 |
|
RU2793167C2 |
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| ANTI-CLL1-SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGENIC RECEPTORS (SCCAR) FOR CANCER IMMUNOTHERAPY | 2016 |
|
RU2731543C2 |
| COMPOSITION FOR TREATING IGF-1R EXPRESSING CANCER | 2016 |
|
RU2728568C2 |
| CD123-SPECIFIC CHIMERIC ANTIGENIC RECEPTORS FOR CANCER IMMUNOTHERAPY | 2015 |
|
RU2727290C2 |
| COMBINATION CANCER THERAPIES TARGETTING CD38 AND TGF-BETA | 2019 |
|
RU2808632C2 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| COMBINATIONS OF ANTIBODIES FOR TREATING CANCER IN SPECIFIC PATIENTS | 2020 |
|
RU2816531C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
